Rapid Relief

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of minor aches and pains of muscles and joints associated with conditions such as simple backache, arthritis, strains, bruises, and sprains.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children 12 years of age and older should carefully remove the backing from the patch and apply the sticky side directly to the affected area. The patch should not be left on the skin for more than a total of 8 hours per day. Application may be repeated as necessary, but should not exceed 3 times daily. After each use, the patch must be discarded.

For children under 12 years of age, the product is not recommended, and consultation with a physician is advised. It is essential to supervise children when they are using this product to ensure safe and appropriate application.

Contraindications

Use of this product is contraindicated in the following situations:

Application on wounds, cuts, damaged, or infected skin is prohibited due to the risk of exacerbating the condition. The product should not be applied to the eyes, mouth, genitals, or any mucous membranes, as this may lead to irritation or adverse reactions. Additionally, tight bandaging or concurrent use with heating pads, including electric heating pads, is contraindicated due to the potential for excessive skin irritation or burns. Furthermore, the simultaneous use of this product with other topical analgesics is not recommended, as it may increase the risk of adverse effects.

Warnings and Precautions

For external use only. In the event of accidental ingestion, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

This product is contraindicated for application on wounds, cuts, damaged, or infected skin. It should not be used on the eyes, mouth, genitals, or any other mucous membranes. In cases of contact with these areas, it is imperative to rinse thoroughly with water.

The product must be used strictly as directed. There have been rare reports of serious burns associated with similar products; therefore, caution is advised. Users should avoid tightly bandaging the area of application or using heating pads, including electric heating pads, as these practices may lead to excessive skin irritation or burns.

Healthcare professionals should advise patients to avoid contact with eyes and mucous membranes, and to refrain from applying the product to wounds or damaged skin. Concurrent use with other topical analgesics is not recommended.

Patients should be instructed to discontinue use and consult a healthcare provider if any of the following occur: worsening of the condition, presence of redness, development of irritation, persistence of symptoms beyond 7 days, or recurrence of symptoms after initial improvement. Additionally, if signs of skin injury such as pain, swelling, or blistering appear at the site of application, medical advice should be sought immediately, as serious burns, although rare, can occur.

Side Effects

Patients should be aware that the product is intended for external use only. In the event of worsening conditions, the presence of redness, development of irritation, or persistence of symptoms beyond 7 days, it is advised to discontinue use and consult a healthcare professional. Additionally, if symptoms resolve and then recur within a few days, medical advice should be sought.

Serious adverse reactions, although rare, may include signs of skin injury such as pain, swelling, or blistering at the site of application. These reactions can indicate the occurrence of serious burns, necessitating immediate medical attention.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Rapid Relief (cold relief patch 5% menthol). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not use this product without consulting a physician. It is essential for caregivers to supervise children during the use of this product to ensure safety and proper administration.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional before using this medication. The safety of this drug during pregnancy has not been established, and potential risks to fetal outcomes are not fully known. Therefore, it is essential for women of childbearing potential to seek medical advice prior to use to ensure appropriate management and consideration of any potential risks.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may indicate an overdose. These may include, but are not limited to, altered mental status, cardiovascular instability, or gastrointestinal disturbances.

Management of an overdose should be guided by the clinical presentation of the patient. Supportive care is paramount, and symptomatic treatment should be initiated as necessary. It is recommended that healthcare professionals consult local poison control centers or toxicology experts for further guidance on the management of overdose cases.

In summary, while specific overdosage information is not available, healthcare professionals should exercise caution and be prepared to act swiftly in the event of an overdose, ensuring that appropriate measures are taken to safeguard patient health.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question.

Postmarketing Experience

Serious burns have been reported in rare cases associated with the use of products of this type. While these events are infrequent, they are considered significant and warrant attention in the context of postmarketing surveillance.

Patient Counseling

Healthcare providers should advise patients to use the product only as directed and to be aware of the potential for serious burns, which, although rare, have been reported with similar products. Patients should be instructed to seek medical help or contact a Poison Control Center immediately if the product is swallowed.

It is important to inform patients not to bandage the area tightly or use the product in conjunction with heating pads, including electric heating pads, as this may lead to excessive skin irritation or burns. Patients should also be cautioned to avoid contact with eyes and mucous membranes, and to refrain from applying the product to wounds or damaged skin.

Healthcare providers should emphasize that the product should not be used simultaneously with other topical analgesics. Patients should be advised to stop using the product and consult a doctor if their condition worsens, if redness or irritation develops, or if symptoms persist for more than 7 days or clear up and then recur within a few days. Additionally, patients should be instructed to seek medical advice if they experience any signs of skin injury, such as pain, swelling, or blistering at the application site, as these may indicate serious burns.

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers, which are essential for identification and inventory management. It is crucial to store the product at a temperature range of 15-30℃ (59-86℉) to maintain its efficacy and stability.

Additionally, the product should be kept out of reach of children to ensure safety. Proper handling and storage conditions are vital to preserve the integrity of the product throughout its shelf life.

Additional Clinical Information

The product is administered topically. For adults and children aged 12 years and older, the patch should be applied to the affected area by carefully removing the backing and placing the sticky side onto the skin. It should not remain on the skin for more than 8 hours in total per day, and can be repeated as necessary, up to three times daily. After a single use, the patch must be discarded. For children under 12 years of age, the product is not recommended without consulting a physician, and adult supervision is advised during use.

Clinicians should counsel patients to consult a health professional if they are pregnant or breastfeeding before using the product. It is important to keep the product out of reach of children, and in the event of accidental ingestion, medical assistance or contact with a Poison Control Center should be sought immediately.

Drug Information (PDF)

This file contains official product information for Rapid Relief, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)